1,3,4-二作为结构动机:SAR方面的进展,以及药物发现应用
Pranshul Awasthi1, Amit Mittal1, Swati1
1Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara (Punjab) 144411, India.
Current topics in medicinal chemistry
|October 31, 2025
概括
1,3,4-亚二醇是一种多功能异环化合物,由于其广泛的生物活性,它在药物化学中表现有前途. 研究强调了其作为开发各种疾病新型治疗剂的核心支架的潜力.
科学领域:
- 药用化学 医学化学
- 有机化学 有机化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 1,3,4-提亚迪亚是一种含有硫和原子的五个分子异环化合物.
- 它独特的结构使其成为开发治疗剂的多功能支架.
- 1,3,4-thiadiazole部分表现出多样化的药理活性,包括抗微生物,抗炎,抗,抗病毒和抗氧化物质.
研究的目的:
- 审查最近关于1,3,4-thiadiazole衍生物的研究.
- 突出结构修改及其对药理学活动的影响.
- 检查与亚二醇衍生物相关的专利 (2019-2024年) 用于疾病应用.
主要方法:
- 科学研究的文献评论.
- 从2019年到2024年的专利文献分析.
- 专注于结构修改和报告的生物活动.
主要成果:
- 1,3,4-提亚醇衍生物具有广泛的生物活性.
- 结构修改显著影响这些化合物的药理特征.
- 最近的专利证明了人们对治疗各种疾病的亚二醇衍生物的持续兴趣.
结论:
- 1,3,4-提亚迪亚是药物发现的一个有前途的核心结构.
- 它的合成可访问性和与多个生物点的相互作用支持其治疗潜力.
- 这一综述强调了1,3,4-thiadiazole在推进下一代药物的能力.
关键词:
第111章 这是一件好事3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 4 5 5 5 5 6 6 7 7 7 7 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 including including including including including including including including including including4 - - 提亚迪亚佐尔的使用这就是为什么SAR SAR SAR.生物活动是生物活动.药物开发是药物的发展.药理学潜力. 药理学潜力.合成方法 合成方法相关概念视频
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.0K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.0K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
898
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
898
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.7K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.7K


